KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Invested Capital (2019 - 2025)

Historic Return on Invested Capital for Alnylam Pharmaceuticals (ALNY) over the last 9 years, with Q3 2025 value amounting to 0.99%.

  • Alnylam Pharmaceuticals' Return on Invested Capital rose 123000.0% to 0.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.99%, marking a year-over-year increase of 123000.0%. This contributed to the annual value of 4.36% for FY2024, which is 28500.0% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Return on Invested Capital is 0.99%, which was up 123000.0% from 0.5% recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Return on Invested Capital peaked at 6.98% during Q4 2022, and registered a low of 13.29% during Q3 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Return on Invested Capital value was 0.57% (recorded in 2021), while the average stood at 0.35%.
  • In the last 5 years, Alnylam Pharmaceuticals' Return on Invested Capital crashed by -145500bps in 2024 and then skyrocketed by 123000bps in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.58% in 2021, then surged by 1307bps to 6.98% in 2022, then tumbled by -79bps to 1.48% in 2023, then plummeted by -191bps to 1.35% in 2024, then grew by 26bps to 0.99% in 2025.
  • Its Return on Invested Capital stands at 0.99% for Q3 2025, versus 0.5% for Q2 2025 and 0.44% for Q1 2025.